Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Absorbable gelatin sponge is a sterile, water-insoluble, porcine-derived hemostatic agent and embolic material. It is widely utilized in surgical procedures to control capillary, venous, and small arterial bleeding when conventional methods are ineffective. In interventional oncology, it serves as a temporary embolic agent for transcatheter arterial chemoembolization (TACE) and portal vein embolization (PVE), particularly for treating hepatocellular carcinoma. The sponge provides a physical matrix that promotes platelet aggregation and accelerates the formation of a fibrin clot, leading to mechanical occlusion of blood vessels. It is typically absorbed within 4 to 6 weeks when implanted in tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on absorbable gelatin sponge.